NASDAQ
1.58USD
+0.08 (+5.33%)
We have scored 14 news catalysts on Lisata Therapeutics, Inc. (LSTA) over the past 12 months. The biggest single-day move next to one of them came Mar 9, 2026, when LSTA closed +20.6%: “Lisata Therapeutics to be acquired by Kuva Labs”. Coverage across the window leans mixed (average ticker sentiment +0.00). Most of the impact sits in short squeeze potential and sector healthcare.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
14.4M
P/E
—
EPS
—
Beta
0.80
52W range
0.9875-5.07
Day range
1.49–1.58
Open
1.54
Prev close
1.50
Volume
47.9K
Avg volume
256.1K
Dividend
0.00
IPO
1999-03-01
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Lisata Therapeutics, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for LSTA: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
